Khaled Yahya Al Zaman

Dr. Khaled Yahya Al Zaman

Cleveland Clinic, Abu Dhabi, Abū Z̧aby, United Arab Emirates
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2024 in Cureus
Verified
Journal Article
Open access
PDF file
EJEman A Jafleh
Eman A Jafleh
FAFatima A Alnaqbi
Fatima A Alnaqbi
HAHind A Almaeeni
Hind A Almaeeni
SFShooq Faqeeh
Shooq Faqeeh
MAMoza A Alzaabi
Moza A Alzaabi
Khaled Yahya Al ZamanKhaled Yahya Al Zaman
Khaled Yahya Al Zaman
Wearable health devices are becoming vital in chronic disease management because they offer real-time monitoring and personalized care. This review explores their effectiveness and challenges across medical fields, including cardiology, respiratory health, neurology, endocrinology, orthopedics, oncology, and mental health. A thorough literature search identified studies focusing on wearable devices’ impact on patient outcomes. In cardiology, wearables have proven effective for monitoring hypertension, detecting arrhythmias, and aiding cardiac rehabilitation. In respiratory health, these devices enhance asthma management and continuous monitoring of critical parameters. Neurological applications include seizure detection and Parkinson’s disease management, with wearables showing promising results in improving patient outcomes. In endocrinology, wearable technology advances thyroid dysfunction monitoring, fertility tracking, and diabetes management. Orthopedic applications include improved postsurgical recovery and rehabilitation, while wearables help in early complication detection in oncology. Mental health benefits include anxiety detection, post-traumatic stress disorder management, and stress reduction through wearable biofeedback. In conclusion, wearable health devices offer transformative potential for managing chronic illnesses by enhancing real-time monitoring and patient engagement. Despite significant improvements in adherence and outcomes, challenges with data accuracy and privacy persist. However, with ongoing innovation and collaboration, we can all be part of the solution to maximize the benefits of wearable technologies in healthcare.

3 June 2024 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
MAMoza A Alzaabi
Moza A Alzaabi
AAAmin Abdelsalam
Amin Abdelsalam
MAMajid Alhammadi
Majid Alhammadi
HHHasan Bani Hani
Hasan Bani Hani
AAAli Almheiri
Ali Almheiri
Khaled Yahya Al ZamanKhaled Yahya Al Zaman
Khaled Yahya Al Zaman
There is a high prevalence of heart failure (HF) worldwide, which has significant consequences for healthcare costs, patient death and quality of life. Therefore, there has been much focus on finding and using biomarkers for early diagnosis, prognostication and therapy of HF. This overview of the research presents a thorough examination of the current state of HF biomarkers and their many uses. Their function in diagnosing HF, gauging its severity and monitoring its response to therapy are all discussed. Particularly promising in HF diagnosis and risk stratification are the cardiac-specific biomarkers, B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. Markers of oxidative stress, extracellular matrix, renal function, inflammation and cardiac peptides have shown promise in evaluating HF severity and prognosis. MicroRNAs and insulin-like growth factor are two emerging biomarkers that have shown potential in helping with HF diagnosis and prognosis.

1 May 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
Khaled Yahya Al ZamanKhaled Yahya Al Zaman
Khaled Yahya Al Zaman
SAShahad Ahmed
Shahad Ahmed
AAAlya Alshamsi
Alya Alshamsi
AAAmna Alshamsi
Amna Alshamsi
BABashar Alshdaifat
Bashar Alshdaifat
BMBashair Mussa
Bashair Mussa
Background: The COVID-19 pandemic which started in November 2019 and since then has led to multiple lockdowns aimed towards controlling the pandemic, these lockdowns contributed to major changes in individuals’ lifestyles including eating patterns and restriction of physical activity due to continues house confinement. Such changes have significantly contributed to weight change, with increasing rates of obesity in the UAE, COVID-19 have posed a major concern to the country’s obesity levels. Aim: To measure the prevalence and investigate the views related to weight change among adults in the UAE during the COVID-19 pandemic. Methods: A cross-sectional study was conducted through a self-administered online questionnaire distributed using social media platforms between February 15th and March 14th, 2021. The sample size was 439 adults in the UAE (18– 59 years), collected by volunteer sampling. Analysis was done using SPSS with a significance of 5.0%. Exclusion criteria included pregnancy and bariatric surgeries history. Results: 51.1% of participants gained weight, 36.2% lost weight and 12.7% maintained their weight. Meal consumption frequency and weight gain were correlated. Consuming fast food resulted in 65.7% of participants gaining weight. 66.2% of people who lost weight during the COVID-19 pandemic did exercise. Stress management and sleeping patterns were not contributing factors to the weight change. 64.4% of the participants who were not satisfied with their weight and believed that they need to make changes in their lifestyle received no guidance from professional personnel to reach their desired weight. Conclusion: In this study, the majority of participants have witnessed an increase in weight. UAE health authorities must provide guidance and support to the population via structured nutritional programs and lifestyle awareness campaigns.

13 January 2025 in Cureus
Verified
Journal Article
Open access
PDF file
Khaled Yahya Al ZamanKhaled Yahya Al Zaman
Khaled Yahya Al Zaman
AAAaesha A Alhebsi
Aaesha A Alhebsi
AAAbdulaziz Almheiri
Abdulaziz Almheiri
HAHind Alhosani
Hind Alhosani
NANada T. Alshehhi
Nada T. Alshehhi
EAEissa S. Alwheibi
Eissa S. Alwheibi
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a complex and often underdiagnosed disorder characterized by impaired water homeostasis, leading to hyponatremia and associated complications. This comprehensive review explores the intersection of SIADH with chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), pulmonary tuberculosis, cystic fibrosis, and interstitial lung disease. The review looks at current evidence on pathophysiology, diagnostic challenges, and treatment approaches, highlighting the need for specialized management strategies to improve patient outcomes. Through an analysis of clinical and observational studies, this review highlights the significant impact of SIADH on morbidity and mortality among patients with respiratory diseases. It illustrates the necessity for further research to refine diagnostic and therapeutic modalities.

14 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WNWasim El Nekidy
Wasim El Nekidy
Khaled Yahya Al ZamanKhaled Yahya Al Zaman
Khaled Yahya Al Zaman
EAEmna Abidi
Emna Abidi
DADiaa Alrahmany
Diaa Alrahmany
IGIslam M Ghazi
Islam M Ghazi
Jihad MallatJihad Mallat
Jihad Mallat
Background: The clinical outcomes of usual doses of Trimethoprim–sulfamethoxazole (TMP/SMZ) for treating S. maltophilia in critically ill patients on renal replacement therapies (RRT) have not been established. We sought to assess the clinical outcomes of TMP/SMZ in patients with sepsis utilizing RRT. Methods: A retrospective study was performed on all critically ill adult patients with S. maltophilia infections who received RRT between May 2015 and January 2022. The primary endpoint was clinical cure while the secondary endpoints were microbiologic cure, 30-day infection recurrence, and mortality. Results: Forty-five subjects met the inclusion criteria. The median age was 70.0 [interquartile range (IQR): 63.5–77] years, 57.8% were males, and the median body mass index was 25.7 [IQR: 22–30.2] kg/m2. Clinical success and failure were reported in 18 (40%) and 27 (60%) cases, respectively. There was no significant difference between the 30-day reinfection rates of both groups; however, mortality was significantly higher in the clinical failure group, involving 12 patients (44.4%), versus none in the clinical success group (p = 0.001). The median daily dose of TMP/SMZ upon continuous veno-venous hemofiltration was 1064 [IQR: 776–1380] mg in the clinical cure group vs. 768 [IQR:540–1200] mg in the clinical failure group (p = 0.035). Meanwhile, the median dose for those who received intermittent hemodialysis was 500 [IQR: 320–928] mg in the clinical success group compared to 640 [IQR: 360–1005] mg in the clinical failure group (p = 0.372). A total of 55% experienced thrombocytopenia, 42% hyperkalemia, and 2.2% neutropenia. The multivariable logistic regression analysis showed that the total daily dose at therapy initiation was the only independent factor associated with clinical success after adjusting for different variables including the body mass index [Odds ratio 1.004; 95% confidence interval: (1–1.007), p = 0.044]. Conclusions: Although the S. maltophilia isolates were reported as susceptible, TMP/SMZ with conventional doses to treat bacteremia and pneumonia in critically ill patients utilizing RRT was associated with high rates of clinical and microbiologic failure as well as with mortality. Larger outcomes and pharmacokinetics studies are needed to confirm our findings.

Verified
Journal Article
Open access
PDF file
EAEmna Abidi
Emna Abidi
WNWasim El Nekidy
Wasim El Nekidy
BABassam Atallah
Bassam Atallah
Khaled Yahya Al ZamanKhaled Yahya Al Zaman
Khaled Yahya Al Zaman
PGPraveen Ghisulal
Praveen Ghisulal
Jihad MallatJihad Mallat
Jihad Mallat
There has been a substantial increase in the use of extracorporeal membrane oxygenation (ECMO) support in critically ill adults. Understanding the complex changes that could affect drugs’ pharmacokinetics (PK) and pharmacodynamics (PD) is of suitable need. Therefore, critically ill patients on ECMO represent a challenging clinical situation to manage pharmacotherapy. Thus, clinicians’ ability to predict PK and PD alterations within this complex clinical context is fundamental to ensure further optimal and, sometimes, individualized therapeutic plans that balance clinical outcomes with the minimum drug adverse events. Although ECMO remains an irreplaceable extracorporeal technology, and despite the resurgence in its use for respiratory and cardiac failures, especially in the era of the COVID-19 pandemic, scarce data exist on both its effect on the most commonly used drugs and their relative management to achieve the best therapeutic outcomes. The goal of this review is to provide key information about some evidence-based PK alterations of the drugs used in an ECMO setting and their monitoring.